R&D | December 05, 2025
DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
BIL also holds an option to increase its equity stake by an additional 15%
Subscribe To Our Newsletter & Stay Updated
